Knowledge on the impact of pharmacogenetics in predicting outcome and toxicity in diffuse large B-cell lymphoma (DLBCL) is scant. We tested 106 consecutive DLBCL treated with R-CHOP21 for 19 single nucleotide polymorphisms (SNPs) from 15 genes potentially relevant to rituximab-CHOP (R-CHOP) pharmacogenetics. Associations of SNPs with event-free survival (EFS) and toxicity were controlled for multiple testing. Genotypic variants of nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase p22phox (CYBA rs4673) and alpha1 class glutathione S-transferase (GSTA1 rs3957357) were independent predictors of EFS (CYBA rs4673 TT genotype: HR 2.06, P ¼ 0.038; GSTA1 rs3957357 CT/TT genotypes: HR 0.38, P ¼ 0.003), after adjusting for International Prognostic Index (IPI). CYBA rs4673 and GSTA1 rs3957357 also predicted outcome in DLBCL subgroups by IPI. Impact of SNPs on toxicity was evaluated in 658 R-CHOP21 courses utilizing generalized estimating equations. NCF4 rs1883112 was an independent predictor against hematologic (odds ratios (OR): 0.45; P ¼ 0.018), infectious (OR: 0.46; P ¼ 0.003) and cardiac toxicity (OR: 0.37; P ¼ 0.023). Overall, host SNPs affecting doxorubicin pharmacodynamics (CYBA rs4673) and alkylator detoxification (GSTA1 rs3957357) may predict outcome in R-CHOP21-treated DLBCL. Also, NCF4 rs1883112, a SNP of NAD(P)H oxidase p40phox, may have a function in protecting against hematologic and nonhematologic toxicity. These results highlight the need to improve characterization of the host genetic background for a better prognostication of DLBCL.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, with patients exhibiting a wide range of outcomes that are clinically predicted by the International Prognostic Index (IPI). 1, 2 Although advances in treatment and identification of clinical indicators have led to improved prognosis and have allowed some tailoring of therapy, a significant fraction of DLBCL patients still fail treatment and die of their disease. [3] [4] [5] Several biological markers may help refine DLBCL stratification into prognostic categories. 6, 7 Virtually all these biological predictors are based on the characteristics of the tumor clone. However, beside the biology of tumor cells, also the genetic background of the host may be relevant for cancer prognostication. [8] [9] [10] [11] In particular, pharmacogenetic studies have documented that host's single nucleotide polymorphisms (SNPs) affecting genes involved in drug metabolism, detoxification and transport are responsible, at least in part, for the interindividual variability in efficacy and toxicity of a given pharmacological treatment. [8] [9] [10] [11] Scant information is available on the impact of pharmacogenetics as a predictor of outcome and toxicity in the context of DLBCL. [12] [13] [14] Rituximab-CHOP (R-CHOP) is the standard treatment for DLBCL. [3] [4] [5] According to available evidence, genes that a priori may be involved in R-CHOP pharmacogenetics encode: (1) cytochrome P450 enzymes, which promote both cyclophosphamide conversion to active compounds and metabolism of vincristine and prednisone; 11 (2) glutathione S-transferase isoforms, which promote detoxification of cyclophosphamide and vincristine and also favor scavenging of doxorubicinderived reactive oxygen species (ROS) that contribute to anthracyclin cytotoxicity; 10, 15 ( 3) ATP-binding cassette transporters, which increase efflux of doxorubicin, vincristine and prednisone from the cell cytoplasm to the extracellular compartment; 9 (4) nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase subunits involved in ROS generation; 14 (5) glucocorticoid receptor 16 and (6) Fcg receptors involved in rituximab antibody-dependent cellular toxicity. 12, 13 This study aimed at verifying whether SNPs modulating gene expression and/or function of enzymes involved in R-CHOP pharmacogenetics may contribute to the prognostic stratification and the prediction of toxicity in DLBCL patients treated with R-CHOP21.
Materials and methods

Patients
The study was based on a consecutive series of 106 newly diagnosed DLBCL treated with R-CHOP21 at the Division of Hematology of the Amedeo Avogadro University of Eastern Piedmont from June 2001 through January 2007. The database was updated for the analysis in April 2008. Median follow-up of alive patients was 33.3 months. No patient was lost at followup. All patients provided informed consent in accordance with local IRB requirements and the Declaration of Helsinki principles. Diagnosis of DLBCL was based on the World Health Organization classification of hematopoietic tumors. 1 A prior history of lymphoproliferative disorders was ruled out in all cases.
Treatment
Patients were planned to receive six to eight courses of R-CHOP21. [3] [4] [5] Patients in complete remission after four R-CHOP21 courses received a total of six courses. Patients in partial remission after four R-CHOP21 courses completed eight courses. Involved field radiotherapy was prescribed as consolidation on sites of primary bulky disease defined according to Ann Arbor criteria. Central nervous system (CNS) prophylaxis with intrathecal methotrexate was administered to patients at risk of CNS dissemination because of involvement of 41 extranodal site plus lactate dehydrogenase (LDH) elevation, or because of bone marrow, epidural, testicular or sinus involvement. Dose reduction was prescribed according to R-CHOP21 guidelines. [3] [4] [5] If patients developed grade 3-4 neutropenia or febrile neutropenia, all subsequent courses were administered with granulocyte colony-stimulating factor (G-CSF) support. If neutropenia persisted during the next course, the dose of cyclophosphamide and doxorubicin was decreased by 25%. For patients with grade 3-4 thrombocytopenia, the dose of cyclophosphamide and doxorubicin was decreased by 25%. If patients developed grade 3-4 neurological toxicity or ileus, the dose of vincristine was decreased by 50%. Chemotherapy was delayed until neutropenia resolved to grade 1 or less, thrombocytopenia resolved to grade 0 and nonhematologic toxicities resolved to grade 1 or less. If hematologic or nonhematologic toxicities did not resolve within a maximum delay of 3 weeks, chemotherapy was discontinued. Support treatment consisted of anti-emetics, antibiotic prophylaxis with levofloxacine, Pneumocystis carinii pneumonia prophylaxis with cotrimoxazole and antiviral prophylaxis with acyclovir. Lamivudine was administered before the start of R-CHOP21 to all hepatitis B virus (HBV) seropositive patients. G-CSF and recombinant human erythropoietin (rhEPO) were prescribed according to guidelines. 17, 18 Red blood cell and platelet transfusions were prescribed in case of Hb o8 g/100 ml and platelet count o20 Â 10 9 per liter, respectively. Hospitalization was prescribed in case of febrile neutropenia or grade 3-4 nonhematologic toxicity. Treatment and control visits, along with registration of toxicities, complete blood count and biochemistry, were scheduled on day 1 of R-CHOP21 administration and on day 10-14 of each course. Response was evaluated at the end of the fourth course and at the end of R-CHOP21 treatment. Follow-up visits were scheduled every 3 months for the first 2 years and every 6 months thereafter.
Data collection
All DLBCL cases included in this study are provided with a large and homogeneous dataset of prospectively collected variables. The following clinical variables were recorded at presentation: date of diagnosis, age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, Ann Arbor stage, number of extranodal sites, B symptoms, bulky disease, liver and bone marrow involvement; LDH (normal range: 200-450 U/l), absolute neutrophil count (ANC), hemoglobin and platelet count, bilirubin (normal range: 0.6-1.2 mg/100 ml), alkaline phosphatase (ALP) (normal range: 90-360 U/l), albumin (normal range: 34-48 g/l), glomerular filtration rate; cardiac ejection fraction, abnormalities on echocardiography, abnormalities on electrocardiogram; HCV, HBV and HIV serology and number and type of comorbidities according to Cumulative Illness Rating Scale. 19 The following variables were recorded during treatment: total number of courses per patient, date and type of response and date of progression. In addition, the following variables were also recorded for each course of R-CHOP21: date of administration, doses of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, delay, dose reduction, utilization of rhEPO and G-CSF, antibiotic treatment, red blood cell and platelet transfusion, days of hospitalization and toxicity. The following variables were recorded during follow-up: date of progression, date of last follow-up visit, date of death, cause of death, late onset cardiotoxicity and second cancers.
SNP genotyping
An educated guess approach was utilized for the selection of genes potentially relevant to R-CHOP pharmacogenetics. [9] [10] [11] [12] [13] [14] 16, 20 SNPs were selected according to the following criteria: (1) nonsynonymous SNPs predicting alteration of protein function; (2) SNPs affecting regulatory regions and predicting altered expression of the gene; (3) SNPs known to be relevant for prediction of outcome or toxicity in other settings and (4) SNPs with a minor allele frequency in the study population 45%. 21 In fact, SNPs whose minor alleles do not reach a given frequency in the study population may not be informative for correlation studies. Sample power analysis estimated that, in our cohort (n ¼ 106), the genotype distribution of SNPs with a minor allele frequency 45% would allow detection of at least 25% difference in 3-year event-free survival (EFS) (a: 0.05; two-tailed test; power: 80%).
Nineteen polymorphisms from 15 genes were analyzed (Supplementary Tables 1S and 2S) . [9] [10] [11] [12] [13] [14] 16, 20 These included SNPs affecting: (1) cytochrome P450 enzymes (CYP2C19 rs4244285, CYP3A5 rs776746); (2) glutathione S-transferase isoforms (GSTA1 rs3957357, GSTM1-null, GSTP1 rs1695, GSTP1 rs1138272); (3) ATP-binding cassette transporters (ABCC2 rs17222723, ABCC2 rs8187710, ABCB1 rs1045642, ABCB1 rs2229109, ABCG2 rs2231142, ABCG2 rs2231137); (4) NAD(P)H oxidase subunits (NCF4 rs1883112, RAC2 rs13058338, CYBA rs4673); (5) glucocorticoid receptor (GR rs41423247); (6) Fcg receptors (FCGR2A rs1801274, FCGR3A rs10127939) and (7) 
Statistical analysis of correlations between SNPs and R-CHOP21 efficacy
The impact of SNPs on R-CHOP21 efficacy was evaluated by EFS. For the purpose of this study, which focused on the pharmacogenetics solely of R-CHOP21 and not of salvage
regimens, overall survival was not considered as a measure of R-CHOP21 efficacy, because it may be influenced by second-line treatment. Response was assessed according to published guidelines. 22 EFS was measured from date of DLBCL diagnosis to date of treatment failure, death or last follow-up. 22 The association between SNPs and EFS was evaluated considering the minor allele of each SNP as acting both in a recessive and in a dominant fashion. Univariate analysis for EFS was performed by KaplanMeier method using log-rank statistics to test for significant associations. False discovery rate (FDR) was used to control for multiple statistical testing for each SNP as acting both in a recessive and in a dominant fashion. 23 Cox proportional hazard regression was used to build a multivariate model for EFS.
Statistical analysis of correlations between SNPs and R-CHOP21 toxicity
Toxicity events were analyzed on a per course basis. 24, 25 Toxicities were graded according to NCI CTC version 0.3 (http:// ctep.cancer.gov/reporting/ctc.html). The association between SNPs and toxicity was evaluated considering the minor allele of each SNP as acting both in a recessive and in a dominant fashion.
Analysis for toxicity was performed by generalized estimating equations (GEE), which adjusts for the clustering of treatment courses within a patient. 26 A GEE model was chosen because multiple observations between courses within the same patient would be expected to violate the independence assumption of standard logistical regression. Toxicity was managed as a binary categorical variable. Binomial distribution with a logit link function was utilized for GEE. The robust Huber/White/sandwich estimator of covariance was applied. The best assumption for working correlation matrix for GEE analysis was selected by using the quasi-likelihood under independence criterion goodness of fit coefficient. The Wald test was used to select the final set of risk factors for retention into the model (Po0.05 to retain). Odds ratios (OR) obtained by GEE models carry the same meaning as OR generated by standard logistic regression models. For a given category, the closer the OR is to 1.00, the more similar is that category to the reference category. On the contrary, the greater or lower the OR is, the greater or lower is the risk of that category compared to the reference category. FDR was used to control for multiple statistical testing for each SNP as acting both in a recessive and in a dominant fashion. 23 All statistical tests were two-sided. Statistical significance was defined as P-value o0.05. The analysis was performed with the Statistical Package for the Social Sciences (SPSS) software version 15.0 (Chicago, IL, USA) and, in the case of FDR, with R statistical package (http://www.r-project.org/).
Results
Clinical characteristics at DLBCL diagnosis and treatment
Clinical characteristics of the cohort at DLBCL diagnosis are representative of the disease ( 
SNPs affecting cyclophosphamide and doxorubicin activity as predictors of EFS in DLBCL treated with R-CHOP21
Univariate log-rank analysis controlled for multiple comparisons by FDR testing identified the GSTA1 rs3957357, CYBA rs4673 Table 4S ). GSTA1 rs3957357 maps to the promoter region of GSTA1, a gene encoding an alpha1 class glutathione S-transferase that facilitates solubility and excretion of cyclophosphamide and its active derivatives. 15 In our cohort, DLBCL patients who carried the GSTA1 rs3957357 CT/TT genotypes displayed a better EFS (3-year EFS: 69.4%; s.e.: 5.7%) compared to patients who carried the GSTA1 rs3957357 CC genotype (3-year EFS: 40.9%; s.e.: 9.1%) (P ¼ 0.024; q ¼ 0.192) (Supplementary Table 4S and Figure 1a) .
CYBA rs4673 is a nonsynonymous SNP affecting CYBA, a gene that encodes the p22phox subunit of the NAD(P)H oxidase complex. 27 We observed that DLBCL patients who carried the CYBA rs4673 TT genotype displayed a poorer EFS (3-year EFS: 42.9%; s.e.: 12.1%) compared to patients who carried the CYBA rs4673 CT/CC genotypes (3-year EFS: 62.9%; s.e.: 5.6%) (P ¼ 0.007; q ¼ 0.168) (Supplementary Table 4S and Figure 1b) .
ABCC2 rs17222723 is a nonsynonymous SNP of the ABCC2 gene that encodes multidrug-resistance-protein 2, an ATPbinding cassette transporter acting as an efflux system for various compounds including doxorubicin and vincristine. 9 In this study, DLBCL patients who carried the ABCC2 rs17222723 AT/AA genotypes displayed a poorer EFS (3-year EFS: 37.5%; s.e.: 11.4%) compared to DLBCL patients who carried the Table 2) . Multivariate analysis adjusted for single IPI variables identified GSTA1 rs3957357 CT/TT genotype (HR: 0.44; 95% CI 0.24-0.82; P ¼ 0.010) and CYBA rs4673 TT genotype (HR: 2.53; 95% CI 1.29-4.98; P ¼ 0.007) as independent predictors of EFS in DLBCL treated with R-CHOP21, along with involvement of 41 extranodal site (HR: 3.64; 95% CI 1.93-6.87; P ¼ 6.5 Â 10 À5 ) ( Table 2 ).
Within the subgroup of DLBCL presenting with favorable IPI 0-2, both the GSTA1 rs3957357 CC genotype and the CYBA rs4673 TT genotype identified a subset of patients displaying short EFS (Figures 2a and b) . Also, within the subgroup of DLBCL presenting with unfavorable IPI 3-5, the GSTA1 rs3957357 CC genotype identified a subset of patients displaying a very poor EFS (Figure 2a ). 
Pharmacogenetics of R-CHOP21 in DLBCL D Rossi et al
The prognostic function of GSTA1 rs3957357 and CYBA rs4673 may not be explained by differences in chemotherapy feasibility or mortality due to toxicity. In fact, DLBCL patients who carried the GSTA1 rs3957357 CT/TT genotypes did not differ from DLBCL patients who carried the GSTA1 rs3957357 
The NCF4 rs1883112 SNP protects against R-CHOP21 toxicities
The impact of SNPs on risk of hematologic and nonhematologic toxicities was assessed in 658 courses of R-CHOP21 administered to 106 DLBCL patients. Because patients experiencing toxicity at a given course may be more prone to have subsequent toxic events, a GEE analysis was chosen for modeling R-CHOP21 toxicity. According to GEE analysis, NCF4 rs1883112, a SNP of the p40phox gene that regulates NAD(P)H oxidase, 27 ,28 recurred as an independent host factor protecting against hematologic toxicity, infection and cardiac toxicity.
Hematologic toxicity. Grade 3-4 hematologic toxicity was observed in 116/658 (17.6%) courses. Based on univariate screening controlled for multiple comparisons, the following SNPs were retained for GEE multivariate analysis for grade 3-4 hematologic toxicity: NCF4 rs1883112 (P ¼ 0.001; q ¼ 0.026), ABCG2 rs2231142 (P ¼ 0.006; q ¼ 0.052) and FCGR2A rs1801274 (P ¼ 0.002; q ¼ 0.026) (Supplementary Table 5S ). Clinical variables that were retained for GEE multivariate analysis for grade 3-4 hematologic toxicity are listed in Table 2 Pharmacogenetic and clinical variables predicting EFS by multivariate analysis in DLBCL treated with R-CHOP21 Variables that entered the analysis were GSTA1 rs3957357 CC vs CT/ TT, CYBA rs4673 CT/CC vs TT, ABCC2 rs17222723 TT vs AT/AA, age p60 years vs age 460 years, ECOG PS p1 vs ECOG PS 41, Ann Arbor stage I-II vs III-IV, LDH p1 Â ULN vs 41 Â ULN, extranodal sites p1 vs extranodal sites 41. Figure 2 Survival curves for event-free survival (EFS) according to GSTA1 rs3957357 and CYBA rs4673 in combination with IPI. Within the subgroup of diffuse large B-cell lymphoma (DLBCL) presenting with favorable IPI 0-2, both the GSTA1 rs3957357 CC (a) and the CYBA rs4673 TT genotypes (b) identified a subset of patients displaying short EFS. Also, within the subgroup of DLBCL presenting with unfavorable IPI 3-5, the GSTA1 rs3957357 CC genotype (a) identified a subset of patients displaying a very poor EFS. Cardiac toxicity. Grade 2-4 cardiac toxicity was observed in 123/658 (18.6%) courses. Based on univariate screening controlled for multiple comparisons, the following SNPs were retained for GEE multivariate analysis for grade 2-4 cardiac toxicity: Table 8S ). Clinical variables that were retained for GEE multivariate analysis for grade 2-4 cardiac toxicity are listed in Supplementary Table 6S . GEE analysis identified NCF4 rs1883112 AG/GG genotype (OR: 0.37; P ¼ 0.023) as an independent predictor of grade 2-4 cardiac toxicity, along with excretory organ function, namely glomerular filtration rate o50 ml/min (OR: 2.27; P ¼ 0.017) and bilirubin 41.2 mg/100 ml (OR: 2.37; P ¼ 0.022) ( Table 3) .
Pharmacogenetics of R-CHOP21 in DLBCL
D Rossi et al SupplementaryNCF4 rs1883112 (P ¼ 1.7 Â 10 À4 ; q ¼ 0.002), GSTP1 rs1695 (P ¼ 0.015; q ¼ 0.078), RAC2 rs13058338 (P ¼ 0.019; q ¼ 0.082), CYBA rs4673 (P ¼ 0.010; q ¼ 0.065), ABCB1 rs2229109 (P ¼ 0.010; q ¼ 0.065), CYP3A5 rs776746 (P ¼ 1.0 Â 10 À4 ; q ¼ 0.002) and FCGR3A rs10127939 (P ¼ 0.039; q ¼ 0.144) (Supplementary
Discussion
In this study, we document that: (1) host SNPs affecting alkylating agent detoxification (GSTA1 rs3957357) and doxorubicin pharmacodynamics (CYBA rs4673) may predict EFS in DLBCL treated with R-CHOP21; and (2) NCF4 rs1883112, a SNP belonging to NAD(P)H oxidase p40phox and regulating ROS generation, recurs as a potential protective genotype against both hematologic and nonhematologic toxicities of R-CHOP21.
The association of GSTA1 rs3957357 and CYBA rs4673 with R-CHOP21 efficacy and DLBCL outcome is biologically plausible and consistent with previous observations in settings other than lymphoma. 10, 15, [29] [30] [31] [32] [33] GSTA1 encodes an alpha1 class glutathione S-transferase that catalyses the conjugation of cyclophosphamide and its active metabolites with glutathione to increase water solubility and facilitate excretion. 15 The GSTA1 rs3957357T minor allele associates with reduced levels of GSTA1 enzyme in healthy individuals, and predicts for X150 Â 10 9 vs o150 Â 10 9 per liter, ALP p1 Â ULN vs 41 Â ULN, glomerular filtration rate X50 vs o50 ml/min, course number 41 vs 1. b Variables that entered GEE analysis for grade 2-4 infective toxicity were GSTA1 rs3957357 CT/CC vs TT, NCF4 rs1883112 AA vs AG/GG, ABCG2 rs2231137 GG vs AG/AA, age p60 years vs 460 years, sex female vs male, ECOG PS p1 vs 41, extranodal sites p1 vs 41, no liver involvement vs liver involvement, ANC at toxicity X1.0 Â 10 9 vs o1.0 Â 10 9 per liter, ALP p1 Â ULN vs 41 Â ULN, glomerular filtration rate X50 vs o50 ml/min, course number 41 vs 1. c Variables that entered GEE analysis for grade 2-4 cardiac toxicity were GSTP1 rs1695 AG/AA vs GG, NCF4 rs1883112 AA vs AG/GG, RAC2 rs13058338 AT/TT vs AA, CYBA rs4673 CT/CC vs TT, ABCB1 rs2229109 GG vs AG, CYP3A5 rs776746 GG vs AG/AA, FCGR3A rs10127939 TT vs AG/AA/AT/GT, age p60 vs 460 years, LDH p1 Â ULN vs 41 Â ULN, extranodal sites p1 vs 41, no liver involvement vs liver involvement, albumin X35 vs o35 g/l, ALP p1 Â ULN vs 41 Â ULN, bilirubin p1.2 vs 41.2 mg/100 ml, glomerular filtration rate X50 vs o50 ml/min, normal echocardiography vs abnormal echocardiography, no history of cardiac disease vs history of cardiac disease, course number p3 vs 43.
Pharmacogenetics of R-CHOP21 in DLBCL D Rossi et al reduced detoxification of alkylating agents, thus increasing tumor cell exposure to drug. 10, 29, 30 In our study, we observed that DLBCL patients carrying the GSTA1 rs3957357 CT/TT genotypes displayed a better EFS compared to DLBCL patients who carried the GSTA1 rs3957357 CC genotype. Interestingly, in addition to DLBCL, the prognostic relevance of GSTA1 rs3957357 in cancer patients treated with cyclophosphamide containing regimens is also documented in breast cancer. In fact, the GSTA1 rs3957357T minor allele has been shown to associate with improved survival of breast cancer patients treated with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or cyclophosphamide, adriamycin and 5-fluorouracil (CAF). 31 Although a formal pharmacokinetic proof is lacking, it is conceivable that improved outcome in both DLBCL and breast cancer may be related to increased levels of cyclophosphamide derivatives mediating increased tumor cell killing.
Beside its impact on efficacy, GSTA1 rs3957357 also impacts on the risk of infective toxicity in DLBCL (this study) as well as in other clinical settings treated with cyclophosphamide containing regimens. 32, 33 These observations further reinforce the involvement of GSTA1 rs3957357 in the pharmacogenetics of cyclophosphamide.
Multivariate analysis selected also CYBA rs4673 as an independent predictor of EFS in DLBCL treated with R-CHOP21. CYBA rs4673 is a nonsynonymous SNP affecting coding exon 4 of the CYBA gene that encodes the p22phox subunit of the NAD(P)H oxidase complex. 27 Tissues from individuals carrying the CYBA rs4673T minor allele have a substantial reduction in ROS generation by NAD(P)H oxidase. 34 Because ROS generation is one of the antitumor mechanisms of doxorubicin, 35 the CYBA rs4673T minor allele is expected to reduce the tumor cytotoxicity of doxorubicin based regimens. According to this model, DLBCL patients treated with R-CHOP21 and carrying the CYBA rs4673 TT genotype displayed a poorer EFS compared to DLBCL patients who carried the CYBA rs4673 CT/CC genotypes.
The heterogeneity of DLBCL outcome is recapitulated by the IPI, which has been generated taking into account both tumorrelated variables and host features represented by age, sex and performance status. 2 Our data demonstrate that the genetic background of the host may add prognostic information when utilized in combination with IPI. In fact, in our series both GSTA1 rs3957357 and CYBA rs4673 identified a subgroup of DLBCL patients that, despite presenting with favorable IPI 0-2, eventually failed R-CHOP21. In addition, GSTA1 rs3957357 further interacts with IPI through the segregation of DLBCL patients presenting with unfavorable IPI 3-5. In fact, DLBCL patients presenting with both unfavorable IPI 3-5 and GSTA1 rs3957357 CC genotype failed R-CHOP21 in virtually all cases.
Neither GSTA1 rs3957357 nor CYBA rs4673 showed an impact on EFS after second-line treatment (data not shown). Lack of impact of these SNPs on EFS after second-line treatment is consistent with the fact that GSTA1 rs3957357 and CYBA rs4673 are not known to influence the metabolism and/or the activity of drugs utilized in second-line, platinum-based regimens that were administered as salvage therapy in this DLBCL cohort. 10 Lack of impact of these SNPs on EFS after second-line treatment may explain the lack of impact on OS (data not shown).
Consistent with previous studies in DLBCL treated with R-CHOP21, our results failed to identify an association between EFS and SNPs of Fcg receptors that are involved in rituximab antibody-dependent cellular toxicity. 12, 13 Lack of association between SNPs of Fcg receptors and lymphoma outcome has also been reported in the context of follicular lymphoma treated with R-CHOP. 36 In a pharmacogenetic study performed in the setting of non-Hodgkin's lymphoma treated with cyclophosphamidecontaining regimens, CYP2C19 rs4244285 has been shown to modulate cyclophosphamide conversion to active metabolites. 37 This observation, however, has not been correlated with outcome or toxicity. 37 In our study, among all SNPs involved in cyclophosphamide pharmacokinetics and including CYP2C19 rs4244285, only GSTA1 rs3957357 displayed a clinical relevance. Overall, our pharmacogenetic data indirectly suggest that detoxification of cyclophosphamide active metabolites by GSTA1 rs3957357, rather than cyclophosphamide bioactivation by CYP2C19 rs4244285, is clinically relevant in the setting of DLBCL treated with R-CHOP21. A formal pharmacogenetic-pharmacokinetic study is required to confirm this association.
In addition to outcome, the pharmacogenetic background of the host appears to be relevant for predicting R-CHOP21 toxicity. This study shows that NCF4 rs1883112 protects against several clinically relevant toxicities occurring in DLBCL patients treated with R-CHOP21. In fact, carriers of the NCF4 rs1883112 G minor allele experience less frequently hematologic, infective and cardiac toxicity. With the limitations of a monoinstitutional series, the protective effect of NCF4 rs1883112 appears to be independent of potentially confounding clinical variables, such as comorbidities, organ function, performance status and dose intensity. NCF4 encodes the p40phox subunit of the NAD(P)H oxidase, which downregulates enzyme function.
27 NCF4 rs1883112 affects the gene promoter with potential consequences on NCF4 expression and ROS generation.
14,28 ROS generation may have a relevant function in several R-CHOP21 toxicities. First, increased exposure to anthracycline-derived ROS is a widely accepted mechanisms of doxorubicin cardiotoxicity. 14, 35 Second, ROS are involved in neutrophil death upon exposure to chemotherapy. 38 Recently, CHOP-induced cardiotoxicity has been shown to associate with selected SNPs of the NAD(P)H oxidase complex and with SNPs of ATP-binding cassette genes.
14 In our series, univariate association was documented between cardiac toxicity and the SNPs NCF4 rs1883112, RAC2 rs13058338 and CYBA rs4673, all affecting the NAD(P)H oxidase multienzyme complex that is involved in ROS generation. Multivariate analysis confirmed the association between NCF4 rs1883112 and cardiac toxicity.
Univariate association was also documented between cardiac toxicity and the SNP ABCB1 rs2229109. ABCB1 is an ATP-binding cassette transporter of several anticancer drugs, including doxorubicin. At least three ABCB1 SNPs, namely rs2229109, rs1045642 and rs2032582, have been associated with functional consequences, drug bioavailability or treatment outcome in several cancers. 9 Two of these ABCB1 SNPs, namely rs2229109 and rs1045642, were previously associated with increased cardiotoxicity in DLBCL treated with CHOP.
14 The SNP ABCB1 rs2032582 has not been included in our study, because a previous evidence failed to show any clinical association in the context of CHOP-treated DLBCL. 14 The fact that the study was performed on a monoinstitutional series of 106 patients may represent a potential limitation. It should be noted, however, that sample analysis showed that the study was sufficiently powered for detecting at least 25% difference in 3-year EFS. Also, given the current lack of pharmacogenetics knowledge in the context of DLBCL, we reasoned that this pilot study would be best performed in a cohort provided with highly homogeneous and complete clinical data. Further studies on independent series are required to validate our model prospectively.
Pharmacogenetics of R-CHOP21 in DLBCL D Rossi et al
These observations suggest that SNPs involved in the pharmacogenetics of R-CHOP21 may provide potential prognostic markers for predicting failure of therapy and toxicity in DLBCL. To date, most new prognostic markers of DLBCL have been derived from the tumor clone biology. 6, 7 This study highlights the need to improve the characterization of the host genetic background for a better prognostication of DLBCL.
